Renal cell carcinoma — an immunogenic tumor where personalized neoantigen vaccines are being evaluated in the adjuvant setting.
Peking University First Hospital is launching a Phase I investigator-initiated trial to evaluate a personalized neoantigen polyepitope peptide vaccine combined with pembrolizumab in advanced renal cell carcinoma. The study aims to enroll 5-8 patients across safety and expansion cohorts to address the high rate of primary or acquired resistance to pembrolizumab monotherapy.
Patrick Ott, MD, PhD is leading a Phase I study for renal cell carcinoma using a personalized neoantigen vaccine. The intervention combines the vaccine with poly-ICLC and ipilimumab.
CancerNetwork discusses the potential for personalized cancer vaccines to transform kidney cancer treatment options. This commentary reflects growing industry interest in expanding neoantigen vaccine indications beyond melanoma and lung cancer into other solid tumor types with unmet needs.
Patrick Ott, MD, PhD is conducting a Phase I study of a personalized NeoAntigen Cancer Vaccine combined with Poly-ICLC and Ipilimumab for renal cell carcinoma. The trial is active but not recruiting, focusing on the safety and immunogenicity of this personalized vaccine platform in kidney cancer.
David Braun, MD, discusses a Phase 2 trial of an individualized neoantigen therapy for renal cell carcinoma (RCC). This coverage signals ongoing clinical validation of personalized approaches in urologic malignancies beyond melanoma and lung cancer.
Investigational neoantigen vaccines targeting renal cell carcinoma (RCC) mutations have been shown to drive durable T-cell activity. This data supports the biological plausibility of targeting somatic mutations in RCC for therapeutic vaccine development.
A study in Nature demonstrates that a neoantigen vaccine generates antitumour immunity in renal cell carcinoma. This peer-reviewed evidence reinforces the mechanistic basis for vaccine-induced immune responses in RCC patients.